CandlesenseCandlesense
AKBA•benzinga•

Akebia Therapeutics Announces That The American Journal Of Kidney Disease Has Published The Results Of FO2CUS, An Open-Label Study Evaluating The Efficacy And Safety Of Vadadustat, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, In Hemodial

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on November 14, 2024 by benzinga

← Back to AKBA News
    Akebia Therapeutics Announces That The American Journal Of Kidney Disease Has Published The Results Of FO2CUS, An Open-Label Study Evaluating The Efficacy And Safety Of Vadadustat, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, In Hemodial | AKBA Stock News | Candlesense